breast cancer - triple negative | |
mBC - TNBC - L2 - PDL1 positive | |
anti-PD-(L)1 | |
pembrolizumab based treatment | |
pembrolizumab alone | KEYNOTE-119 ... KEYNOTE-119 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -